Eli Lilly’s Eiry Roberts Joins Neurocrine as Chief Medical Officer

Eiry Roberts is Neurocrine Biosciences’ (NASDAQ: [[ticker:NBIX]]) new chief medical officer. Roberts comes to the San Diego biotech company from Eli Lilly (NYSE: [[ticker:LLY]]), where her roles included serving as vice president of clinical pharmacology, and vice president of R&D in the company’s biomedicines business unit. Roberts succeeds Christopher O’Brien, who will retire in February. Neurocrine says O’Brien will continue in a consulting role to the company. Neurocrine develops and markets drugs that treat neurologic, psychiatric, and endocrine disorders.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan